Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. has a positive outlook driven by several fundamental factors, including faster-than-expected growth in the spine market and increased sales from its Enabling Technologies segment, which contribute to higher expected margins. The company is also positioned to see strong free cash flow and improved organic growth, supported by an optimistic revenue guidance that may lead to incremental multiple expansion. Additionally, with ongoing initiatives like the NuVasive integration and in-sourcing manufacturing, there is potential for meaningful gross margin expansion and stabilization of EBITDA margins to around 34-35% by 2026.

Bears say

The negative outlook on Globus Medical's stock is primarily driven by potential risks associated with slower-than-expected growth in the spine market and possible revenue disruptions stemming from ongoing mergers with NuVasive and Nevro. Additional concerns include expectations for low-single-digit revenue growth with flat margins, alongside potential challenges in competitive dynamics and sluggish performance of key product launches in the enabling technologies segment. Furthermore, the capital environment may adversely impact robotic purchasing, which could lead to additional downward risks for future revenue estimates and overall financial performance.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.